The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma

We focused on the therapeutic effect of pembrolizumab for metastatic urothelial carcinoma (mUC) and evaluated predictive factors for improving clinical outcomes. We conducted a retrospective multicenter cohort study of patients with mUC who received pembrolizumab. The endpoint was to evaluate the as...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomioka-Inagawa, Risa, Nakane, Keita, Enomoto, Torai, Tomioka, Masayuki, Taniguchi, Tomoki, Ishida, Takashi, Ozawa, Kaori, Takagi, Kimiaki, Ito, Hiroki, Takeuchi, Shinichi, Kawase, Makoto, Kawase, Kota, Kato, Daiki, Takai, Manabu, Iinuma, Koji, Yokoi, Shigeaki, Nakano, Masahiro, Koie, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313086/
https://www.ncbi.nlm.nih.gov/pubmed/35884914
http://dx.doi.org/10.3390/biomedicines10071609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313086/
https://www.ncbi.nlm.nih.gov/pubmed/35884914
http://dx.doi.org/10.3390/biomedicines10071609

Ejemplares similares